Contains Nonbinding Recommendations

Draft Guidance on Rifabutin

This draft guidance, once finalized, will represent the Food and Drug Administration's (FDA's) current thinking on this topic. It does not create or confer any rights for or on any person and does not operate to bind FDA or the public. You can use an alternative approach if the approach satisfies the requirements of the applicable statutes and regulations. If you want to discuss an alternative approach, contact the Office of Generic Drugs.

<table>
<thead>
<tr>
<th>Active ingredient:</th>
<th>Rifabutin</th>
</tr>
</thead>
<tbody>
<tr>
<td>Form/Route:</td>
<td>Capsule/Oral</td>
</tr>
<tr>
<td>Recommended studies:</td>
<td>2 studies</td>
</tr>
</tbody>
</table>

1. Type of study: Fasting  
   Design: Single-dose, two-way crossover *in-vivo*  
   Strength: 150 mg  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments:  

2. Type of study: Fed  
   Design: Single-dose, two-way crossover *in-vivo*  
   Strength: 150 mg  
   Subjects: Healthy males and nonpregnant females, general population.  
   Additional Comments:  

---

Analytes to measure (in appropriate biological fluid): Rifabutin in plasma

Bioequivalence based on (90% CI): Rifabutin

Waiver request of in-vivo testing: Not Applicable

Dissolution test method and sampling times:

Please note that a Dissolution Methods Database is available to the public at the OGD website at [http://www.accessdata.fda.gov/scripts/cder/dissolution/](http://www.accessdata.fda.gov/scripts/cder/dissolution/). Please find the dissolution information for this product at this website. Please conduct comparative dissolution testing on 12 dosage units each of all strengths of the test and reference products. Specifications will be determined upon review of the application.

Recommended Feb 2010